1 Boosting the innovation machine in Pharma R&D
event strap

Boosting the innovation machine in Pharma R&D

information we require

please check before submitting



Unfortunately the document is not available at this current time, however if you leave your details we'll get it to you as soon as we can.

Please fill in all the information requested. It is very important you enter this information correctly so we can contact you with the document.

Privacy statement »

Manage your email preferences »

Remember my details Information

Information
Remember my details
We place a 'cookie' on your computer so next time you visit us you don't need to fill in all these details

An interview with François-Henri Boissel, CEO of Novadiscovery, on Pharma R&D biggest challenges

McKinsey has predicted that Big Data could reduce research and development costs for pharmaceutical makers by $40 billion to $70 billion. They anticipate that data will form the cornerstone of future value-based assessment and also be used for gaining market access, and enhance competitiveness.
Companies who can exploit big data and analytics will have the potential to improve their productivity and efficiency, especially in the discovery, research and development of new products, experts say. 

In this interview, we asked François-Henri Boissel, CEO of Novadiscovery, for his view on the traditional drug R&D process, and how it could be modified to better predict real world performance and adverse events.

Download the report now to hear:

  • The potential of big data solutions in Pharma
  • Considerations of the traditional R&D paradigm and its clinical trial phases
  • How we can produce better drugs with a high potential of entering the market?
  • The idea behind in-silico modelling and simulation
  • How organisations can take advantage of their data to manage their global operations efficiently

Download the ebook now to gain an exclusive 15% discount to attend the Big Data in Pharma Briefing.